Sangamo Therapeutics

Name

Sangamo Therapeutics

Legal name

Sangamo Therapeutics, Inc.

Website

https://sangamo.com

Company type

Public

Founded year

1995

Operating status

Closed

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Gene Therapy / Genomic Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Genomic medicine
• Zinc finger proteins
• Gene therapy
• AAV capsid delivery
• Clinical-stage biotechnology

Headquarters

HQ city

Richmond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Licensing Royalties & Milestone Payments: Revenue generated from out-licensing of proprietary STAC-BBB capsid and epigenetic regulation platform to Genentech, Astellas, and Eli Lilly. Includes $88 million received to date and up to $4.6 billion in potential future milestones across these partnerships. Genentech deal (August 2024) was worth up to $2 billion; Astellas STAC-BBB deal (December 2024) up to $1.3 billion; Eli Lilly deal (2025) up to $1.4 billion for gene therapy vector licensing.
2. Collaboration Revenue: Revenue from collaboration agreements and license-related activities with pharmaceutical partners. Sangamo reported Q4 2025 revenue of $14.23 million, down significantly from consensus estimate of $40.25 million, reflecting lumpy milestone-based revenue typical of clinical-stage biotech.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Sangamo Therapeutics is a clinical-stage genomic medicine company that designs and develops gene therapies using its proprietary zinc finger protein (ZFP) technology platform. The company engineers novel AAV capsid delivery systems for tissue-targeted genomic medicines, including its proprietary STAC-BBB capsid for central nervous system (CNS) delivery, and applies its SIFTER capsid discovery and MINT modular integrase platforms to develop treatments for severe genetic diseases. Revenue is generated primarily through licensing and collaboration agreements with global pharmaceutical partners such as Genentech, Astellas, Eli Lilly, Takeda, and Alexion.

Product overview

Sangamo Therapeutics is a clinical-stage genomic medicine company built around three core proprietary technology platforms — the Zinc Finger Platform (used for genome regulation, gene knockout, base editing, and gene activation), the Delivery Platform (AAV and lentivirus vectors including the SIFTER capsid discovery engine and engineered capsids like STAC-BBB), and the Modular Integrase (MINT) Platform (protein-guided genome editing for large DNA integration) — together forming a unified architecture that supports both wholly owned and partnered therapeutic programs. The platforms underpin a pipeline of clinical and preclinical programs across neurology (ST-503 for small fiber neuropathy, ST-506 for prion disease, ST-502 for synucleinopathies, plus Tauopathies partnered with Genentech, ALS/FTD with Alexion, and Huntington's with Takeda), other genomic diseases (Isaralgagene civaparvovec/ST-920 for Fabry disease acquired by Astellas; Giroctocogene fitelparvovec for hemophilia A returned by Pfizer), and cell therapies (TX200 CAR-Treg for renal transplantation, BIVV003 for sickle cell disease, and oncology programs). Following the Chapter 11 bankruptcy filing in June 2026, Eli Lilly acquired the zinc finger, capsid delivery, MINT platform, and ST-506 prion disease program, while Astellas acquired ST-920; the company is operating under strategic alternatives evaluation.

Differentiator

Problem solved

Functional benefit

Products and services

• Zinc Finger Protein (ZFP) Platform

Quantifiable outcome

• ST-920 (isaralgagene civaparvovec) showed mean annualized eGFR slope of 1.965 mL/min/1.73m² at 52 weeks across 32 patients in Phase 1/2 STAAR study, supporting FDA Accelerated Approval pathway
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered flagship and core.

• Eli LillyflagshipOEM/ Whitelabel/ Licensing Partner · 4 April 2025$1.4 billion licensing deal with Eli Lilly to develop a gene therapy vector using Sangamo's STAC-BBB capsid for neurological disease treatment, with options to expand. Across multiple STAC-BBB licenses, up to $4.6 billion in potential milestones. In bankruptcy, Lilly serves as stalking horse bidder for capsid delivery, zinc finger, MINT platform, and prion disease program (ST-506) at $50 million.
• PfizercoreOEM/ Whitelabel/ Licensing Partner · 31 December 2024Historical partner for giroctocogene fitelparvovec (SB-525/PF-07055480) hemophilia A gene therapy. Pfizer announced positive Phase 3 AFFINE topline results in July 2024 but terminated the licensing agreement at the end of 2024, returning full rights to Sangamo.
• Astellas PharmaflagshipOEM/ Whitelabel/ Licensing Partner · 20 December 2024Worldwide exclusive license agreement allowing Astellas to use Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, for up to five neurological disease targets. Deal involves upfront fees and milestone payments totaling up to $1.3 billion, plus royalties on potential sales. Building on 2024 license, Astellas agreed to acquire Fabry disease program ST-920 (isaralgagene civaparvovec) for $25M (potentially $50M with milestones) as stalking horse bidder in bankruptcy.
• Genentech (Roche)flagshipOEM/ Whitelabel/ Licensing Partner · 1 August 2024Global epigenetic regulation and capsid delivery license agreement for novel genomic medicines for neurodegenerative diseases, focused on tau gene (Alzheimer's and other tauopathies) plus a second undisclosed neurology target. Deal worth up to $2 billion per Roots Analysis epigenetics market report referencing August 2024 announcement.
• Takeda PharmaceuticalcoreStrategic or Co-development PartnerCo-development partnership developing preclinical genome engineering product candidates to treat Huntington's Disease, utilizing zinc finger repressors designed to differentially downregulate the mutated disease-causing huntingtin gene (HTT gene) while preserving expression of the normal version of the gene.
• Alexion (AstraZeneca Rare Disease)coreStrategic or Co-development PartnerCollaboration for development and commercialization of therapeutics using zinc finger transcription factors (ZF-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene (previously partnered with Pfizer, transitioned to Alexion).

Scale indicators13 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• CRISPR Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-based ex vivo and in vivo therapies for hemoglobinopathies, oncology, and regenerative medicine. Directly comparable to Sangamo as a programmable genome-editing platform company with partnered and wholly-owned clinical programs.
• Editas Medicine: Clinical-stage gene editing company using CRISPR/Cas9 and Cas12a systems to develop in vivo and ex vivo therapies for rare diseases including sickle cell, retinal disorders, and oncology. Directly comparable genome-editing platform peer to Sangamo's zinc finger technology.
• Beam Therapeutics: Clinical-stage precision genetic medicine company developing base-editing therapeutics for sickle cell disease, alpha-1 antitrypsin deficiency, and other diseases. Direct gene-editing peer to Sangamo with comparable platform-based business model and partner-driven revenue.
• Intellia Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-based in vivo and ex vivo therapies, including NTLA-2001 for transthyretin amyloidosis. Direct platform peer competing with Sangamo in programmable genomic medicines with major pharma partnerships (Regeneron, Novartis).
• Prime Medicine: Clinical-stage biotech developing prime editing, a next-generation gene editing technology that can make precise edits without double-strand breaks. Direct platform peer comparable to Sangamo's MINT and zinc finger platforms in the gene editing modality landscape.

Broad incumbents

• uniQure: Established AAV-based gene therapy company with approved product (Hemgenix for hemophilia B) and clinical programs in Huntington's disease (AMT-130) and Fabry disease. Closely comparable to Sangamo in CNS/rare disease gene therapy focus and AAV delivery emphasis.
• REGENXBIO: Clinical-stage AAV gene therapy company with proprietary NAV technology platform licensing to multiple partners and internal pipeline in retinal, CNS, and metabolic diseases. Comparable as an AAV delivery platform licensor competing in the same capsid-delivery space as Sangamo's STAC-BBB.
• BioMarin Pharmaceutical: Established rare disease biotech with multiple approved products (Roctavian for hemophilia A gene therapy) and a clinical pipeline across genetic disorders. Broad incumbent comparable to Sangamo's rare disease gene therapy positioning, particularly in hemophilia and metabolic disorders.
• Sarepta Therapeutics: Commercial-stage gene therapy company with multiple approved AAV-based treatments for Duchenne muscular dystrophy and a clinical pipeline in CNS and rare diseases. Broad incumbent competing in the same AAV gene therapy and rare disease space as Sangamo.
• bluebird bio: Gene therapy company with approved products for beta-thalassemia, sickle cell disease (Lyfgenia), and cerebral adrenoleukodystrophy. Comparable to Sangamo's ex vivo cell therapy programs (BIVV003 for sickle cell, TX200 CAR-Treg) and rare disease focus.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/sangamotx
• LinkedInlinkedin.com/company/sangamo-therapeutics
• Facebookfacebook.com/SangamoTx

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sangamo Therapeutics